Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes drug HM15275 enters Mid-Stage trial

NCT ID NCT07527650

Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 6 times

Summary

This study tests a new medicine called HM15275 in people with type 2 diabetes. The goal is to see if it can lower blood sugar levels (HbA1c) safely over 36 weeks. About 180 adults who manage their diabetes with diet, exercise, or metformin will take part. Half will get the drug, half a placebo, and neither they nor their doctors will know which.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria 1. Participant's age at the time of signing the informed consent: * United States: 18 to 75 years (inclusive) 2. Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening 3. Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for at least 3 months prior to screening 4. BMI ≥25 kg/m² and ≤50 kg/m² 5. Body weight change \<5% over the past 3 months prior to screening 6. Capable of giving signed informed consent and willing to comply with all protocol procedures Key Exclusion Criteria 1. Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening 2. Poor glycemic control (fasting plasma glucose \>270 mg/dL) 3. History of diabetic ketoacidosis or severe hypoglycemia within 6 months 4. Clinically significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months) 5. History of pancreatitis or factors increasing the risk of pancreatitis 6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 7. Clinically significant liver disease, renal impairment (eGFR \<60 mL/min/1.73 m²), or abnormal laboratory findings at screening 8. Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T2DM Type 2 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Accel Research Sites - DeLand

    RECRUITING

    DeLand, Florida, 32720, United States

  • AdventHealth Translational Research Institute

    NOT_YET_RECRUITING

    Orlando, Florida, 32804, United States

  • Centricity Research Columbus

    RECRUITING

    Columbus, Ohio, 43213, United States

  • Centricity Research IRT - DBA IACT Health Columbus Piedmont

    RECRUITING

    Columbus, Georgia, 31904, United States

  • Charter Research

    RECRUITING

    Orlando, Florida, 32803, United States

  • Clay Platte Family Medicine

    RECRUITING

    Kansas City, Missouri, 64151, United States

  • Desert Clinical Research

    RECRUITING

    Mesa, Arizona, 85123, United States

  • Jefferson City Medical Center

    RECRUITING

    Jefferson City, Missouri, 65109, United States

  • K2 Medical Research The Villages LLC

    RECRUITING

    The Villages, Florida, 32159, United States

  • Lucas Research, Inc.

    RECRUITING

    Morehead City, North Carolina, 28557, United States

  • Manassas Clinical Research Center

    RECRUITING

    Manassas, Virginia, 20110, United States

  • Methodist Physicians Clinic

    RECRUITING

    Fremont, Nebraska, 68025, United States

  • Olympus Family Medicine

    RECRUITING

    Salt Lake City, Utah, 84117, United States

  • Santa Rosa Medical Centers of Nevada

    RECRUITING

    Las Vegas, Nevada, 89119, United States

  • The South Bend Clinic

    RECRUITING

    South Bend, Indiana, 46617, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.